COVID-19 and antimalarials. Have we been doing it wrong all along?
Eur J Pharmacol
; 891: 173694, 2021 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: covidwho-893746
ABSTRACT
In the context of the current SARS-CoV-2 pandemic, associations of drugs which interfere with specific steps of the viral infectious cycle are currently being exploited as therapeutic strategies since a specific treatment by vaccination is still unavailable. A widespread association of repurposed agents is the combination of the antimalarial drug Hydroxychloroquine and the macrolide antibiotic Azithromycin in the setting of clinical trials. But a closer analysis of their mechanism of action suggests that their concomitant administration may be impractical, and this is supported by experimental data with other agents of the same classes. However a sequential administration of the lysosomotropic antimalarial with the addition of the macrolide proton pump inhibitor after the first has reached a certain threshold could better exploit their antiviral potential.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Azitromicina
/
Reposicionamiento de Medicamentos
/
SARS-CoV-2
/
COVID-19
/
Tratamiento Farmacológico de COVID-19
/
Hidroxicloroquina
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Eur J Pharmacol
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS